Traci le
Nurse Practitioner · Garden Grove, CANPI 1225417124
Payments from drug & device makers
Across 151 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$631
- Abbott$498
- Novo Nordisk$391
- Dexcom, Inc.$380
- Boehringer Ingelheim$254
- Insulet Corporation$229
- plus $590 from 12 others
What the payments were for
- Food & beverage$2,962100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $631 |
| Abbott | 32 | $498 |
| Novo Nordisk | 18 | $391 |
| Dexcom, Inc. | 15 | $380 |
| Boehringer Ingelheim | 10 | $254 |
| Insulet Corporation | 10 | $229 |
| AstraZeneca | 9 | $167 |
| Xeris Pharmaceuticals, Inc. | 5 | $111 |
| Cequr Corporation | 4 | $81 |
| Amphastar Pharmaceuticals, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Mannkind Corporation | 2 | $30 |
| Radius Health, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| IBSA Pharma Inc. | 1 | $18 |
| BD | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
How this compares
$2,973 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $286,946 |
| JardianceEmpagliflozin | 128 | $138,063 |
| TrulicityDulaglutide | 73 | $95,530 |
| JanuviaSitagliptin Phosphate | 67 | $72,352 |
| RybelsusSemaglutide | 44 | $52,206 |
| FarxigaDapagliflozin Propanediol | 45 | $38,941 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $37,833 |
| MounjaroTirzepatide | 28 | $34,464 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $29,198 |
| TradjentaLinagliptin | 34 | $24,590 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $22,022 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $13,891 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 123 | $13,548 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $10,269 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $7,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba | $391 | $343,941348 claims |
| Boehringer IngelheimJardiance, Tradjenta | $254 | $162,654162 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $631 | $129,995101 claims |
| AstraZenecaFarxiga | $167 | $38,94145 claims |
| Sanofi-aventis U.S. LLCLantus | $43 | $3,23922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Garden Grove
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.